JMI LABS IS NOW PART OF LEARN MORE

In vitro activity of the orally bioavailable ceftibuten/VNRX-7145 (VNRX-5236 etzadroxil) combination against a challenge set of Enterobacterales pathogens carrying molecularly characterized β-lactamase genes

In vitro activity of the orally bioavailable ceftibuten/VNRX-7145 (VNRX-5236 etzadroxil) combination against a challenge set of Enterobacterales pathogens carrying molecularly characterized β-lactamase genes by Mendes RE, Rhomberg, PR, Watters AA, Castanheira M in J. Antimicrob. Chemother. 77(3): 2022, 689-694.

Frequency of spontaneous resistance for gepotidacin and levofloxacin against a collection of Gram-negative and Gram-positive organisms via single-step mutational analysis

Frequency of spontaneous resistance for gepotidacin and levofloxacin against a collection of Gram-negative and Gram-positive organisms via single-step mutational analysis. Lead author: SJ Ryan Arends presented at ASM Microbe 2022, June 9-13, Washington DC

Ceftibuten-avibactam (fixed 4 μg/mL), ceftibuten, and ceftazidime-avibactam (fixed 4 μg/mL) broth microdilution quality control ranges using a CLSI M23 (2018) multi-laboratory study design

Ceftibuten-avibactam (fixed 4 μg/mL), ceftibuten, and ceftazidime-avibactam (fixed 4 μg/mL) broth microdilution quality control ranges using a CLSI M23 (2018) multi-laboratory study design. Lead Author: MD Huband presented at ASM Microbe 2022, June 9-13, 2022, Washington DC

 

Comparison of the VITEK2 Advanced Expert System phenotyping and genetic characterization of β-Lactamase Genes for Enterobacterales isolates from North and Latin America

Comparison of the VITEK2 Advanced Expert System phenotyping and genetic characterization of β-Lactamase genes for Enterobacterales isolates from North and Latin America. Lead author: CG Carvalhaes, presented at ASM Microbe 2022, June 9-13, Washington DC, USA

Poster #2427

The NCI and NIAID collaborative screen of the NPNPD Natural Product Fraction Library identified selective antimicrobial activity from natural source

The NCI and NIAID collaborative screen of the NPNPD Natural Product Fraction Library identified selective antimicrobial activity from natural source. Lead author: Leonard Duncan presented at ASM Microbe 2022, June 9-13, Washington DC

MIC predictions for four β-lactam agents for Escherichia coli and Klebsiella pneumoniae from a large surveillance program using genomic data and a machine learning model

MIC predictions for four β-lactam agents for Escherichia coli and Klebsiella pneumoniae from a large surveillance program using genomic data and a machine learning model presented by M Castanheira at ASM Microbe 2022, June 9-13, Washington DC

High-throughout screening of the Natural Product Discovery Fraction Library from the National Cancer Institute identified fractions with selective antimicrobial activity

High-throughout screening of the Natural Product Discovery Fraction Library from the National Cancer Institute identified fractions with selective antimicrobial activity presented by SJ Ryan Arends at ASM Microbe 2022, June 9-13, Washington DC.

Evaluation of bactericidal activity, post-antibiotic, and sub-inhibitory effect of gepotidacin against various Gram-negative and Gram-positive isolates

Evaluation of bactericidal activity, post-antibiotic, and sub-inhibitory effect of gepotidacin against various Gram-negative and Gram-positive isolates. Lead Author: SJ Ryan Arends presented at ASM Microbe 2022, June 9-13, Washington DC

Prediction of MIC values for four β-lactam agents for Escherichia coli and Klebsiella pneumoniae from a large surveillance program using genomic data and a machine learning model

Prediction of MIC values for four β-lactam agents for Escherichia coli and Klebsiella pneumoniae from a large surveillance program using genomic data and a machine learning model. Lead author: Cory Hubler, presented at ASM Microbe 2022, June 9-13, Washington DC

In vitro activity of manogepix against 1,435 fungal isolates collected worldwide during the SENTRY surveillance program (2020)

In vitro activity of manogepix against 1,435 fungal isolates collected worldwide during the SENTRY surveillance program (2020). Lead Author: MD Huband presented at ASM Microbe 2022, June 9-13, 2022, Washington DC

Detection of the carbapenem-hydrolyzing CTX-M-15 variant, CTX-M-33, among carbapenem-nonsusceptible Klebsiella pneumoniae isolates from Poland

Detection of the carbapenem-hydrolyzing CTX-M-15 variant, CTX-M-33, among carbapenem-nonsusceptible Klebsiella pneumoniae isolates from Poland. Lead author Mariana Castanheira presented at ASM Microbe 2022, June 9-13, Washington DC

Comparison of MIC results for gepotidacin by agar dilution and broth microdilution methods for various Gram-positive and Gram-negative species

Comparison of MIC results for gepotidacin by agar dilution and broth microdilution methods for various Gram-positive and Gram-negative species. Lead author SJ Ryan Arends. Presented at ASM Microbe 2022, June 9-13, Washington DC

Impact of COVID-19 on the antifungal susceptibility profiles of isolates collected in a global surveillance program that monitors invasive fungal infections

Impact of COVID-19 on the antifungal susceptibility profiles of isolates collected in a global surveillance program that monitors invasive fungal infections by Pfaller MA, Carvalhaes CG, DeVries S, Rhomberg PR, Castanheira M in Med. Mycol. J. 2022; 6 (60): myac028.

In vitro activity of a novel aminomethylcycline antibacterial (KBP-7072) against clinical isolates with molecularly characterized tetracycline resistance mechanisms

In vitro activity of a novel aminomethylcycline antibacterial (KBP-7072) against clinical isolates with molecularly characterized tetracycline resistance mechanisms by Pfaller MA, Li L, Liu Q, Zhang J, Huband MD, Lindley JM, Mendes RE in J. Glob. Antimicrob. Resist. 3(4): 2021, dlab177.

In vitro potency and spectrum of the novel polymycin MRX-8 tested against clinical isolates of Gram-negative bacteria

In vitro potency and spectrum of the novel polymycin MRX-8 tested against clinical isolates of Gram-negative bacteria by Duncan LR, Wang W, Sader HS in Antimicrob. Agents Chemother. 2022; 66 (5): 10.1128.

Ceftobiprole activity against Gram-positive and Gram-negative pathogens causing bone and joint infections in the United States from 2016 to 2020

Ceftobiprole activity against Gram-positive and Gram-negative pathogens causing bone and joint infections in the United States from 2016 to 2020 by Duncan LR, Hamed KA, Smart JI, Pfaller MA, Flamm RK, Mendes RE published in Diagn. Microbiol. Infect. Dis. 2022; 103: 115713.

Selection of the appropriate avibactam concentration for use with ceftibuten in broth microdilution susceptibility testing

Selection of the appropriate avibactam concentration for use with ceftibuten in broth microdilution susceptibility testing by Sader HS, Lindley J, Deshpande LM, Doyle T, Castanheria M. in Diagn. Microbiol. Infect. Dis. 2002; 103 (2) 115673.

Evaluation of rezafungin provisional CLSI clinical breakpoints and epidemiological cutoff values tested against a worldwide collection of contemporaneous invasive fungal isolates (2019 to 2020)

Evaluation of rezafungin provisional CLSI clinical breakpoints and epidemiological cutoff values tested against a worldwide collection of contemporaneous invasive fungal isolates (2019 to 2020) by Carvalhaes CG, Klauer AL, Rhomberg PR, Pfaller MA, Castanheira, M in J. Clin. Microbiol. 2022; 60 (4) doi: 10.1128/jcm.02449-21

Evaluation of rezafungin provisional CLSI clinical breakpoints and epidemiological cutoff values tested against a worldwide collection of contemporaneous invasive fungal isolates (2019 to 2020)

Evaluation of rezafungin provisional CLSI clinical breakpoints and epidemiological cutoff values tested against a worldwide collection of contemporaneous invasive fungal isolates (2019 to 2020) by Carvalhaes C, Klauer A, Rhomberg PR, Pfaller MA, Castanheira M in J. Clin. Microbiol. 2022; 60 (4), https://doi.org/10.1128/jcm.02449-21.

Antimicrobial activity of dalbavancin against Gram-positive bacteria isolated from patients hospitalized with bloodstream infection in United States and European medical centers (2018-2020)

Antimicrobial activity of dalbavancin against Gram-positive bacteria isolated from patients hospitalized with bloodstream infection in United States and European medical centers (2018-2020) by Sader, HS, Castanheira, M, Huband MD, Shortridge, D, Carvalhaes, CG, Mendes, RM in Eur. J. Clin. Microbiol. Infect. Dis. 2022; 41, 867-873.

In Vitro Activity of Cefiderocol against U.S. and European Gram-Negative Clinical Isolates Collected in 2020 as Part of the SENTRY Antimicrobial Surveillance Program

In Vitro Activity of Cefiderocol against U.S. and European Gram-Negative Clinical Isolates Collected in 2020 as Part of the SENTRY Antimicrobial Surveillance Program. By Shortridge D, Streit JM, Mendes R, and Castanheira M published in Microbiol. Spectr. 2022; 10 (2),  e02712-21.

Antimicrobial Activity of Gepotidacin Against Recent Clinical Isolates of Escherichia coli Collected from Japan in 2019-2020

Antimicrobial Activity of Gepotidacin Against Recent Clinical Isolates of Escherichia coli Collected from Japan in 2019-2020. Lead author: SJ Ryan Arends. Japanese Association of Infectious Diseases (JAID) 22-23 April 2022.

Antimicrobial Activity of New Beta-Lactam/Beta-Lactamase Inhibitor Combinations against Pseudomonas aeruginosa and Enterobacterales from Patients with Pneumonia in Intensive Care Units

Antimicrobial Activity of New Beta-Lactam/Beta-Lactamase Inhibitor Combinations against Pseudomonas aeruginosa and Enterobacterales from Patients with Pneumonia in Intensive Care Units. Lead author: HS Sader presented at American Thoracic Society May 13-18, 2022, San Francisco, CA, USA

Antimicrobial Activity of Dalbavancin and Comparators against Gram-positive Bacteria Causing Bacteraemia in Patients with Skin and Skin Structure Infections (2017-2021)

Antimicrobial Activity of Dalbavancin and Comparators against Gram-positive Bacteria Causing Bacteraemia in Patients with Skin and Skin Structure Infections (2017-2021). Lead author: HS Sader presented at European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 23-26, 2022, Lisbon, Portugal

Antimicrobial Susceptibility of Organisms Isolated from Complicated UTI in Europe: Results from the SENTRY Antimicrobial Surveillance Program (2019-2021)

Antimicrobial Susceptibility of Organisms Isolated from Complicated UTI in Europe: Results from the SENTRY Antimicrobial Surveillance Program (2019-2021). Lead author: CG Carvalhaes presented at European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 23-26, 2022, Lisbon, Portugal
Poster # 1114

Lefamulin Activity against Bacterial Pathogens Typically Causing Pneumonia Collected from European Medical Centres in 2020 and 2021

Lefamulin Activity against Bacterial Pathogens Typically Causing Pneumonia Collected from European Medical Centres in 2020 and 2021. Lead author: HS Sader presented at European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 23-26, 2022, Lisbon, Portugal
Poster #1119

Cefiderocol In Vitro Activity against Molecularly Characterized Acinetobacter baumannii-calcoaceticus complex and Pseudomonas aeruginosa Clinical Isolates Causing Infection in Europe and Adjacent Regions (2020)

Cefiderocol In Vitro Activity against Molecularly Characterized Acinetobacter baumannii-calcoaceticus complex and Pseudomonas aeruginosa Clinical Isolates Causing Infection in Europe and Adjacent Regions (2020). Lead author: RE Mendes presented at European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 23-26, 2022, Lisbon, Portugal
Poster #1163

Prevalence of Carbapenemases and Antimicrobial Activity of Aztreonam-Avibactam and Comparator Agents Among a Global Collection of Enterobacterales

Prevalence of Carbapenemases and Antimicrobial Activity of Aztreonam-Avibactam and Comparator Agents Among a Global Collection of Enterobacterales. Lead author: M Castanheira, presented at European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 23-26, 2022, Lisbon, Portugal
Poster #2164

Comparison Analysis of In vitro Activity of Cefiderocol and Comparator Agents against Molecularly Characterized Carbapenem-resistant Enterobacterales Clinical Isolates Causing Infections in Europe and Surrounding Regions (2020)

Comparison Analysis of In vitro Activity of Cefiderocol and Comparator Agents against Molecularly Characterized Carbapenem-resistant Enterobacterales Clinical Isolates Causing Infections in Europe and Surrounding Regions (2020). Lead author: RE Mendes presented at European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 23-26, 2022, Lisbon, Portugal
Poster #1158

Activity of Cefiderocol and Comparators against US isolates of Pseudomonas aeruginosa, Acinetobacter baumannii-calcoaceticus species complex, and Stenotrophomonas maltophilia, including Carbapenem-Resistant Isolates from the SENTRY Antimicrobial Surveillance Program (2020-2021)

Activity of Cefiderocol and Comparators against US isolates of Pseudomonas aeruginosa, Acinetobacter baumannii-calcoaceticus species complex, and Stenotrophomonas maltophilia, including Carbapenem-Resistant Isolates from the SENTRY Antimicrobial Surveillance Program (2020-2021). Lead author: D Shortridge presented at European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 23-26, 2022, Lisbon, Portugal
Poster #1099

Activity of Cefiderocol and Comparators against US Enterobacterales, including Carbapenem-Resistant Isolates, from the SENTRY Antimicrobial Surveillance Program (2020-2021)

Activity of Cefiderocol and Comparators against US Enterobacterales, including Carbapenem-Resistant Isolates, from the SENTRY Antimicrobial Surveillance Program (2020-2021). Lead author: D Shortridge presented at European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 23-26, 2022, Lisbon, Portugal
Poster #01091

Antifungal Activity of Isavuconazole and Comparator Agents against Contemporaneous Mucorales Isolates from USA, Europe, and Asia-Pacific

Antifungal Activity of Isavuconazole and Comparator Agents against Contemporaneous Mucorales Isolates from USA, Europe, and Asia-Pacific. Lead author: C Carvalhaes presented at European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 23-26, 2022, Lisbon, Portugal
Poster #1148

Performance of the VITEK 2 Advanced Expert System (AES) as a Rapid Tool for Reporting Antimicrobial Susceptibility Testing (AST) in Enterobacterales

Performance of the VITEK 2 Advanced Expert System (AES) as a Rapid Tool for Reporting Antimicrobial Susceptibility Testing (AST) in Enterobacterales. Lead author: C Carvalhaes presented at European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 23-26, 2022, Lisbon, Portugal
Poster #1139

Activity of Meropenem Combined with the β-Lactamase Inhibitor Xeruborbactam and Comparator Agents Tested Against Challenging Gram-negative Organisms

Activity of Meropenem Combined with the β-Lactamase Inhibitor Xeruborbactam and Comparator Agents Tested Against Challenging Gram-negative Organisms. Lead author: M Castanheira presented at European Congress of Clinical Microbiology and Infectious Diseaes (ECCMID), April 23-26, 2022, Lisbon, Portugal
Poster #01593

Activity of Cefiderocol and Comparators against European Isolates of Pseudomonas aeruginosa, Acinetobacter baumannii-calcoaceticus complex, and Stenotrophomonas maltophilia from the SENTRY Antimicrobial Surveillance Program (2020-2021)

Activity of Cefiderocol and Comparators against European Isolates of Pseudomonas aeruginosa, Acinetobacter baumannii-calcoaceticus complex, and Stenotrophomonas maltophilia from the SENTRY Antimicrobial Surveillance Program (2020-2021). Lead author: D Shortridge presented at European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 23-26, 2022, Lisbon, Portugal
Poster #1063

In Vitro Evaluation of Delafloxacin Activity Against Contemporary European Isolates from Community-Acquired Pneumonia and Lower Respiratory Tract Infections: Results from the SENTRY Antimicrobial Surveillance Program (2018-2021)

In Vitro Evaluation of Delafloxacin Activity Against Contemporary European Isolates from Community-Acquired Pneumonia and Lower Respiratory Tract Infections: Results from the SENTRY Antimicrobial Surveillance Program (2018-2021). Lead author: D Shortridge presented at European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 23-26, 2022, Lisbon, Portugal
Poster #00563

Bloodstream Infections in Europe: Aetiology and Antimicrobial Susceptibility Results from the SENTRY Antimicrobial Surveillance Program (2019-2021)

Bloodstream Infections in Europe: Aetiology and Antimicrobial Susceptibility Results from the SENTRY Antimicrobial Surveillance Program (2019-2021). Lead author: HS Sader presented at European Congress of Clinical Microbiology and Infections Diseases (ECCMID), April 23-26, 2022, Lisbon, Portugal
Poster #391

Oritavancin Activity Against Gram-positive Isolates Responsible for Intra-Abdominal Infections in Europe and Surrounding Regions During 2015-2019

Oritavancin Activity Against Gram-positive Isolates Responsible for Intra-Abdominal Infections in Europe and Surrounding Regions During 2015-2019. Lead author: CG Carvalhaes presented at European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 23-26, 2022, Lisbon, Portugal
Poster #466

Comparative Activity of Newer β-Lactam/β-Lactamase Inhibitor Combinations against Pseudomonas aeruginosa from Patients in ICU of US Medical Centres in 2021

Comparative Activity of Newer β-Lactam/β-Lactamase Inhibitor Combinations against Pseudomonas aeruginosa from Patients in ICU of US Medical Centres in 2021. Lead author: HS Sader, presented at European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 23-26, 2022, Lisbon, Portugal

Endemicity of Pseudomonas aeruginosa Producing IMP-18 and/or VIM-2 Metallo-β-Lactamases from the High-Risk Clone ST111 in Central America

Endemicity of Pseudomonas aeruginosa Producing IMP-18 and/or VIM-2 Metallo-β-Lactamases from the High-Risk Clone ST111 in Central America. Lead author: LM Deshpande presented at European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 23-26, 2022, Lisbon, Portgual
Poster #01136

In Vitro Activity of Gepotidacin and Comparators Against a Collection of E. coli and S. saprophyticus Urine Isolates Collected Worldwide During 2019-2021

In Vitro Activity of Gepotidacin and Comparators Against a Collection of E. coli and S. saprophyticus Urine Isolates Collected Worldwide During 2019-2021. Lead author: SJR Arends presented at European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 23-26, 2022, Lisbon, Portugal
Poster #01015

Activity of Meropenem-Vaborbactam and Comparators Against European Carbapenem-Resistant Enterobacterales Isolates Producing KPC Carbapenemase (2018-2020)

Activity of Meropenem-Vaborbactam and Comparators Against European Carbapenem-Resistant Enterobacterales Isolates Producing KPC Carbapenemase (2018-2020). Lead author: D Shortridge presented at European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 23-26, 2022, Lisbon, Portugal
Poster #567

Epidemiology of Escherichia coli Surveillance Isolates Causing Urinary Tract Infections in Europe and In Vitro Activity of Gepotidacin (2019-2020)

Epidemiology of Escherichia coli Surveillance Isolates Causing Urinary Tract Infections in Europe and In Vitro Activity of Gepotidacin (2019-2020). Lead author: RE Mendes presented at European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 23-26, 2022, Lisbon, Portugal
Poster #01030

Antimicrobial Susceptibility of Enterobacterales Causing Infections in Intensive Care Unit Patients: The Role of New β-Lactamase Inhibitor Combinations

Antimicrobial Susceptibility of Enterobacterales Causing Infections in Intensive Care Unit Patients: The Role of New β-Lactamase Inhibitor Combinations. Lead author: CG Carvalhaes, presented at European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 23-26, 2022, Lisbon, Portugal

Evaluation of Gepotidacin Activity when Combined with Select Antimicrobial Agents and Tested Against Bacterial Isolates Using Checkerboard Methodology

Evaluation of Gepotidacin Activity when Combined with Select Antimicrobial Agents and Tested Against Bacterial Isolates Using Checkerboard Methodology. Lead author: SJR Arends presented at European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 23-26, 2022, Lisbon, Portugal
Poster #L0184

Activity of Cefiderocol and Comparators against European Enterobacterales including Carbapenem-Resistant Isolates

Activity of Cefiderocol and Comparators against European Enterobacterales including Carbapenem-Resistant Isolates. Lead author: D Shortridge presented at European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 23-26, 2022, Lisbon, Portugal
Poster #1050

Antimicrobial Activity of Aztreonam-avibactam and Comparator Agents against Ceftazidime-avibactam-resistant Enterobacterales (2019-2021)

Antimicrobial Activity of Aztreonam-avibactam and Comparator Agents against Ceftazidime-avibactam-resistant Enterobacterales (2019-2021). Lead author: HS Sader presented at European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 23-26, 2022, Lisbon, Portugal
Poster #381

Lefamulin Activity against a Contemporary Global Collection of Staphylococcus aureus (SENTRY 2020-2021)

Lefamulin Activity against Bacterial Pathogens Typically Causing Pneumonia Collected from European Medical Centres in 2020 and 2021. Lead author: HS Sader presented at European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 23-26, 2022, Lisbon, Portugal
Poster #1128

Dalbavancin Activity against Bacterial Isolates from Pediatric Patients: Results from the International Dalbavancin Evaluation of Activity (IDEA) Program for the United States and Europe (2019-2021)

Dalbavancin Activity against Bacterial Isolates from Pediatric Patients: Results from the International Dalbavancin Evaluation of Activity (IDEA) Program for the United States and Europe (2019-2021). Lead author: HS Sader presented at St Jude/PIDS Pediatric Infectious Diseases Research Conference, March 3-5, 2022. Virtual conference

Antimicrobial activities of aztreonam-avibactam and comparator agents tested against Enterobacterales from European hospitals analysed by geographic region and infection type (2019-2020)

Antimicrobial activities of aztreonam-avibactam and comparator agents tested against Enterobacterales from European hospitals analysed by geographic region and infection type (2019-2020). by Sader HS, Mendes RE, Arends SJR, Carvalhaes CG and Castanheira M. published in Eur. J. Clin. Microbiol. Infect. Dis. 2022; 41 (3): 477-487